Back to Search
LYUBA VARTICOVSKI, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1326231143Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
51037(MA)
Research & Publications (20)
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
PMID 19416831·Proc Natl Acad Sci U S A·2009
8-other
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
PMID 19074725·Blood·2009
4-observational
The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane.
PMID 18644871·Mol Cell Biol·2008
7-preclinical
Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones.
PMID 18584488·Nutr Cancer·2008
7-preclinical
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.
PMID 18570671·BMC Cancer·2008
7-preclinical
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
PMID 18394172·Mol Cancer·2008
7-preclinical
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
PMID 18382425·Br J Cancer·2008
8-other
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
PMID 18241344·Breast Cancer Res·2008
7-preclinical
Harnessing genetically engineered mouse models for preclinical testing.
PMID 17362899·Chem Biol Interact·2008
6-review
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
PMID 18645008·Mol Cancer Ther·2008
8-other
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
PMID 17404101·Clin Cancer Res·2007
7-preclinical
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.
PMID 17363573·Cancer Res·2007
8-other
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
PMID 17974983·Cancer Res·2007
7-preclinical
Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation.
PMID 16707476·Cancer Res·2006
7-preclinical
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
PMID 17085670·Clin Cancer Res·2006
8-other
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
PMID 16798938·Mol Pharmacol·2006
7-preclinical
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.
PMID 16288013·Cancer Res·2005
8-other
Computerized case history--an effective tool for management of patients and clinical trials.
PMID 16160235·Stud Health Technol Inform·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- NAT'L CANCER INSTITUTE, 10 CENTER DRIVE
BETHESDA, MD 20892 - Phone
- (301) 496-0498
Quick Facts
- NPI
- 1326231143
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile